Copyright Nasdaq. Minimum 15 minutes delayed.

Investors & Media

Download Library

Date Title Documents

Cowen & Co. 38th Annual Healthcare Conference

LEERINK Partners 7th Annual Global Healthcare Conference

Noble Capital Markets' Fourteenth Annual Investor Conference Presentation

Dicerna Pharmaceuticals Corporate Overview January 2018

GalXC TM RNAi Platform Enables Potent and Durable RNAi-Mediated Inhibition of Hepatitis B Virus in Preclinical Models

DCR-PHXC:A new approach for treating all Primary Hyperoxalurias by inhibiting LDHA

Oxalate Production in Primary Hyperoxaluria Types 1, 2 and 3 and the Role of LDH in the Liver

PHYOS: An Observational Study of Patients with Primary Hyperoxaluria Type 1

Dicerna US Tides May 2017 Presentation

GalXC cGMP Manufacturing Experience Presentation